Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017
May 04 2017 - 8:01AM
Zug, Switzerland, May 4, 2017 - Auris Medical
Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in otolaryngology, today announced that it will report its
financial results for the first quarter of 2017 on Thursday, May
11, 2017. Following the announcement, Auris Medical's management
team will host a live conference call and webcast at 8:00 am
Eastern Time (2:00 pm Central European Time) to discuss the
Company's financial results and to provide a general business
update.
To participate in this conference call, dial
1-877-280-3459 (USA) or +1-646-254-3374 (International), and enter
passcode 5733572. A live webcast of the conference call can be
accessed on the Investor Relations section of the Auris Medical
website at www.aurismedical.com. A replay will be available
approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology. The Company is focused on the
Phase 3 development of treatments for acute inner ear hearing loss
(AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by
way of intratympanic administration with biocompatible gel
formulations. In addition, Auris Medical is pursuing intranasal
betahistine for Meniere's disease and vestibular vertigo (AM-125)
as well as early-stage research and development projects. The
Company was founded in 2003 and is headquartered in Zug,
Switzerland. The shares of Auris Medical Holding AG trade on the
NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024